X-ray crystal structure of human heme oxygenase-1 in complex with 1-(adamantan-1-yl)-2-(1H-imidazol-1-yl)ethanone: A common binding mode for imidazole-based heme oxygenase-1 inhibitors

Journal of Medicinal Chemistry

Volumn 51, Issue 19, 2008, Pages 5943-5952

  Rahman, Mona N ^a   Vlahakis, Jason Z ^a   Szarek, Walter A ^a   Nakatsu, Kanji ^a   Jia, Zongchao ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1 (ADAMANTAN 1 YL) 2 (1H IMIDAZOL 1 YL)ETHANONE; 2 [2 (4 CHLOROPHENYL)ETHYL] 2 [(1H IMIDAZOL 1 YL)METHYL] 1,3 DIOXOLANE; 4 (4 BROMOPHENYL) 1 (1H 1,2,4 TRIAZOL 1 YL) 2 BUTANONE; HEME OXYGENASE 1; HEME OXYGENASE INHIBITOR; IMIDAZOLE; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; COMPLEX FORMATION; CRYSTAL STRUCTURE; HYDROPHOBICITY; MOLECULAR DOCKING; NONHUMAN; RAT; STRUCTURE ANALYSIS; X RAY DIFFRACTION;

ADAMANTANE; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; ELECTROSTATICS; ENZYME INHIBITORS; HEME OXYGENASE-1; HUMANS; IMIDAZOLES; MODELS, MOLECULAR; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 53549129271     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm800505m     Document Type: Article

References (45)

1. Maines, M. D. The heme oxygenase system: a regulator of second messenger gases. Annu. Rev. Pharmacol. Toxicol. 1997, 37, 517-554.
2. Vreman, H. J.; Wong, R. J.; Stevenson, D. K. In Carbon Monoxide and Cardiovascular Function; Wang, R., Ed.; CRC Press: Boca Raton, FL, 2002; p 273.
3. Maines, M. D. Heme oxygenase: function, multiplicity, regulatory mechanisms, and clinical applications. FASEB J. 1988, 2, 2557-2568.
4. Hayashi, S.; Omata, Y.; Sakamoto, H.; Higashimoto, Y.; Hara, T.; Sagara, Y.; and Noguchi, M. Characterization of rat heme oxygenase-3 gene. Implication of processed pseudogenes derived from heme oxygenase-2 gene. Gene 2004, 336, 241-250.
5. Ryter, S. W.; Alam, J.; Choi, A. M. Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications. Physiol. Rev. 2006, 86, 583-650.
6. Lee, T. S.; Chau, L. Y. Heme oxygenase-1 mediates the anti-inflammatory effect of interleukin-10 in mice. Nat. Med. 2002, 8, 240-246.
7. Lee, T. S.; Tsai, H. L.; Chau, L. Y. Induction of heme oxygenase-1 expression in murine macrophages is essential for the anti-inflammatory effect of low dose 15-deoxy-delta 12,14-prostaglandin J2. J. Biol. Chem. 2003, 278, 19325-19330.
8. Imuta, N.; Hori, O.; Kitao, Y.; Tabata, Y.; Yoshimoto, T.; Matsuyama, T.; Ogawa, S. Hypoxia-mediated induction of heme oxygenase type I and carbon monoxide release from astrocytes protects nearby cerebral neurons from hypoxia-mediated apoptosis. Antioxid. Redox. Signaling 2007, 9, 543-552.
9. Brouard, S.; Otterbein, L. E.; Anrather, J.; Tobiasch, E.; Bach, F. H.; Choi, A. M.; Soares, M. P. Carbon monoxide generated by heme oxygenase 1 suppresses endothelial cell apoptosis. J. Exp. Med. 2000, 192, 1015-1026.
10. Brouard, S.; Berberat, P. O.; Tobiasch, E.; Seldon, M. P.; Bach, F. H.; Soares, M. P. Heme oxygenase-1-derived carbon monoxide requires the activation of transcription factor NF-kappa B to protect endothelial cells from tumor necrosis factor-alpha-mediated apoptosis. J. Biol. Chem. 2002, 277, 17950-17961.
11. Kim, H. P.; Ryter, S. W.; Choi, A. M. CO as a cellular signaling molecule. Annu. Rev. Pharmacol. Toxicol. 2006, 46, 411-449.
12. Liu, X. M.; Chapman, G. B.; Wang, H.; Durante, W. Adenovirus-mediated heme oxygenase-1 gene expression stimulates apoptosis in vascular smooth muscle cells. Circulation 2002, 105, 79-84.
13. Abraham, N. G.; Kappas, A. Pharmacological and clinical aspects of heme oxygenase. Pharmacol. Rev., in press.
14. Fang, J.; Akaike, T.; and Maeda, H. Antiapoptotic role of heme oxygenase (HO) and the potential of HO as a target in anticancer treatment. Apoptosis 2004, 9, 27-35.
15. Fang, J.; Sawa, T.; Akaike, T.; Akuta, T.; Sahoo, S. K.; Khaled, G.; Hamada, A.; and Maeda, H. In vivo antitumor activity of pegylated zinc protoporphyrin: targeted inhibition of heme oxygenase in solid tumor. Cancer Res. 2003, 63, 3567-3574.
16. Fang, J.; Sawa, T.; Akaike, T.; Greish, K.; Maeda, H. Enhancement of chemotherapeutic response of tumor cells by a heme oxygenase inhibitor, pegylated zinc protoporphyrin. Int. J. Cancer 2004, 109, 1-8.
17. Luo, D.; Vincent, S. R. Metalloporphyrins inhibit nitric oxide-dependent cGMP formation in vivo. Eur. J. Pharmacol. 1994, 267, 263-267.
18. Meffert, M. K.; Haley, J. E.; Schuman, E. M.; Schulman, H.; and Madison, D. V. Inhibition of hippocampal heme oxygenase, nitric oxide synthase, and long-term potentiation by metalloporphyrins. Neuron 1994, 13, 1225-1233.
19. Grundemar, L.; Ny, L. Pitfalls using metalloporphyrins in carbon monoxide research. Trends Pharmacol. Sci. 1997, 18, 193-195.
20. Vlahakis, J. Z.; Kinobe, R. T.; Bowers, R. J.; Brien, J. F.; Nakatsu, K.; Szarek, W. A. Synthesis and evaluation of azalanstat analogues as heme oxygenase inhibitors. Bioorg. Med. Chem. Lett. 2005, 15, 1457-1461.
21. Vlahakis, J. Z.; Kinobe, R. T.; Bowers, R. J.; Brien, J. F.; Nakatsu, K.; and Szarek, W. A. Imidazole-dioxolane compounds as isozyme-selective heme oxygenase inhibitors. J. Med. Chem. 2006, 49, 4437-4441.
22. Roman, G.; Riley, J. G.; Vlahakis, J. Z.; Kinobe, R. T.; Brien, J. F.; Nakatsu, K.; Szarek, W. A. Heme oxygenase inhibition by 2-oxysubstituted 1-(1H-imidazol-1-yl)-4-phenylbutanes: effect of halogen substitution in the phenyl ring. Bioorg. Med. Chem. 2007, 15, 3225-3234.
23. Kinobe, R. T.; Vlahakis, J. Z.; Vreman, H. J.; Stevenson, D. K.; Brien, J. F.; Szarek, W. A.; Nakatsu, K. Selectivity of imidazole-dioxolane compounds for in vitro inhibition of microsomal haem oxygenase isoforms. Br. J. Pharmacol. 2006, 147, 307-315.
24. Sugishima, M.; Higashimoto, Y.; Oishi, T.; Takahashi, H.; Sakamoto, H.; Noguchi, M.; Fukuyama, K. X-ray crystallographic and biochemical characterization of the inhibitory action of an imidazole-dioxolane compound on heme oxygenase. Biochemistry 2007, 46, 1860-1867.
25. Lad, L.; Schuller, D. J.; Shimizu, H.; Friedman, J.; Li, H.; Ortiz de Montellano, P. R.; Poulos, T. L. Comparison of the heme-free and bound crystal structures of human heme oxygenase-1. J. Biol. Chem. 2003, 278, 7834-7843.
26. Sun, J.; Wilks, A.; Ortiz de Montellano, P. R.; Loehr, T. M. Resonance Raman and EPR spectroscopic studies on heme-heme oxygenase complexes. Biochemistry 1993, 32, 14151-14157.
27. Schuller, D. J.; Wilks, A.; Ortiz de Montellano, P. R.; Poulos, T. L. Crystal structure of human heme oxygenase-1. Nat. Struct. Biol. 1999, 6, 860-867.
28. Lad, L.; Wang, J.; Li, H.; Friedman, J.; Bhaskar, B.; Ortiz de Montellano, P. R.; Poulos, T. L. Crystal structures of the ferric, ferrous, and ferrous-NO forms of the Asp140Ala mutant of human heme oxygenase-1: catalytic implications. J. Mol. Biol. 2003, 330, 527-538.
29. Rivera, M.; Caignan, G. A.; Astashkin, A. V.; Raitsimring, A. M.; Shokhireva, T. K.; Walker, F. A. Models of the low-spin iron(III) hydroperoxide intermediate of heme oxygenase: magnetic resonance evidence for thermodynamic stabilization of the d(xy) electronic state at ambient temperatures. J. Am. Chem. Soc. 2002, 124, 6077-6089.
30. Ebing, D. D. General Chemistry; Houghton Mifflin Company: Boston, MA, 1996.
31. Bianchetti, C. M.; Yi, L.; Ragsdale, S. W.; Phillips, G. N., Jr. Comparison of apo- and heme-bound crystal structures of a truncated human heme oxygenase-2. J. Biol. Chem. 2007, 282, 37624-37631.
32. Gottlieb, H. E.; Kotlyar, V.; Nudelman, A. NMR chemical shifts of common laboratory solvents as trace impurities. J. Org. Chem. 1997, 62, 7512-7515.
33. Schuller, D. J.; Wilks, A.; Ortiz de Montellano, P. R.; Poulos, T. L. Crystallization of recombinant human heme oxygenase-1. Protein Sci. 1998, 7, 1836-1838.
34. Wilks, A.; Ortiz de Montellano, P. R. Rat liver heme oxygenase. High level expression of a truncated soluble form and nature of the mesohydroxylating species. J. Biol. Chem. 1993, 268, 22357-22362.
35. Wilks, A.; Black, S. M.; Miller, W. L.; Ortiz de Montellano, P. R. Expression and characterization of truncated human heme oxygenase (hHO-1) and a fusion protein of hHO-1 with human cytochrome P450 reductase. Biochemistry 1995, 34, 4421-4427.
36. Wang, J.; Niemevz, F.; Lad, L.; Huang, L.; Alvarez, D. E.; Buldain, G.; Poulos, T. L.; Ortiz de Montellano, P. R. Human heme oxygenase oxidation of 5- and 15-phenylhemes. J. Biol. Chem. 2004, 279, 42593-42604.
37. Wilks, A.; Medzihradszky, K. F.; Ortiz de Montellano, P. R. Heme oxygenase active-site residues identified by heme-protein cross-linking during reduction of CBrCl3. Biochemistry 1998, 37, 2889-2896.
38. Vreman, H. J.; Stevenson, D. K. Heme oxygenase activity as measured by carbon monoxide production. Anal. Biochem. 1988, 168, 31-38.
39. Cook, M. N.; Nakatsu, K.; Marks, G. S.; McLaughlin, B. E.; Vreman, H. J.; Stevenson, D. K.; Brien, J. F. Heme oxygenase activity in the adult rat aorta and liver as measured by carbon monoxide formation. Can. J. Physiol. Pharmacol. 1995, 73, 515-518.
40. Otwinowski, Z.; Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Macromol. Crystallogr., Part A 1997, 276, 307-326.
41. Schuttelkopf, A. W.; van Aalten, D. M. PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr., Sect. D.: Biol. Crystallogr. 2004, 60, 1355-1363.
42. Collaborative Computational Project, Number 4. The CCP4 suite: programs for protein crystallography. Acta Crystallogr., Sect. D.: Biol. Crystallogr. 1994, 50, 760-763.
43. Holm, L.; Park, J. DaliLite workbench for protein structure comparison. Bioinformatics 2000, 16, 566-567.
44. DeLano, W. L. The PyMOL Molecular Graphics System, version 0.99rc6; DeLano Scientific: Palo Alto, CA, 2002.
45. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 1998, 19, 1639-1662.